Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy

Stanford Health Care

Global nLPHL One Working Group (GLOW) Research Roadmap for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.

Global nLPHL One Working Group (GLOW) Research Roadmap for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Pediatric blood & cancer Palese, M., Advani, R. H., Biney-Amissah, D., Birz, S., Collins, G. P., Hoppe, R. T., Kelly, K. M., Page-Kirby, C., Binkley, M. S., Flerlage, J. E. 2025: e31646

Abstract

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare, indolent lymphoma lacking an evidence-based standard of care. NLPHL research has been challenging due to its classification, unique features, and rarity. The Global nLPHL One Working Group (GLOW) launched in 2020 to accelerate NLPHL research internationally across all ages and stages and to establish a global standard of care. GLOW identified six core aims and 19 activities in its strategic roadmap to overcome historical research challenges, establish a research pipeline to inform a global standard of care, and disseminate findings. Once its prospective trials launch, GLOW will leverage this roadmap to study other rare lymphomas.

View details for DOI 10.1002/pbc.31646

View details for PubMedID 40059286